Skip to main content
Monday 19 May 2025
twitter linkedin facebook rss
User account menu
  • Subscribe
Home
Pharmaphorum menu first category
  • News
  • Views & Analysis
  • Deep Dive
    • Research & Development
    • Market Access
    • Oncology
    • Artificial Intelligence
    • Patients & Partnerships
    • Commercialisation
    • Previous Editions
  • Webinars
  • Podcasts
  • Videos
  • White Papers
  • Events
Pharmaphorum
close
    SECTION
    • News
    • Views & Analysis
    • Deep Dive
      • Research & Development
      • Market Access
      • Oncology
      • Artificial Intelligence
      • Patients & Partnerships
      • Commercialisation
      • Previous Editions
    • Webinars
    • Podcasts
    • Videos
    • White Papers
    • Events
Channels
    Channels
    • Sales & Marketing
    • R&D
    • Digital
    • Market Access
    • Oncology
    • Patients
    • Spotlight On
Channels
  • Sales & Marketing
  • R&D
  • Digital
  • Market Access
  • Oncology
  • Patients
  • Spotlight On
    SUB NAVIGATION
    • Live Coverage
    • Partner Content
    • About us
    • Work for us
    • Contribute
    • Contact us
    • Advertise

Newsletters and Deep Dive digital magazine

 
 
Sign up
twitter linkedin facebook rss
Sign in

Deep Dive

R&D
R&D Contraceptive pills condoms and intrauterine device

Research and Development

R&D
Deep Dive's research and development 2025 edition out now banner

Deep Dive: Research and Development 2025

Every breakthrough in medicine, every new treatment that changes lives, starts with research. 

R&D
drug illustration with hand and brain

Cheminformatics 101: The science behind smarter drug design

R&D
illustrative search visual

Breaking through financial barriers to clinical trials: How ...

R&D
DNA chromosomes genes

The UK as clinical trials powerhouse: An overview of MHRA re...

R&D
chess piece

Regulating the invisible hand: Inside the FDA's AI playbook

  • Load more results

Editor's Picks

  1. World first as infant gets personalised CRISPR therapy
  2. Sanofi pledges a $20 billion investment programme in the US
  3. Novo makes fresh obesity play with $2.2bn Septerna deal
  4. RFK Jr defends HHS cuts, measles stance in Congress hearings
  5. Novo Nordisk's dropping share price spells the end for CEO
News
Regeneron swoops on genetic testing firm 23andMe

Regeneron swoops on genetic testing firm 23andMe

DNA testing company 23andMe looks destined to be taken over by a pharma company, as Regeneron agrees a $256 million acquisition deal.

/themes/custom/pharmaphorum_theme/library/img/article-label-image/ondemand.png
Market Access
Bridging research and clinical guidelines
Sponsored

Bridging research and clinical guidelines – interactive stra...

Medical affairs is evolving. Understanding how to harness real-world data and digital insights is essential.

Pharmaphorum Menu
  • Digital
    • News
    • Views & Analysis
    • Deep Dive
    • Webinars
    • Podcasts
    • Video
    • White Papers
    • Event
  • Market Access
    • News
    • Views & Analysis
    • Deep Dive
    • Webinars
    • Podcasts
    • Video
    • White Papers
    • Event
  • Oncology
    • News
    • Views & Analysis
    • Deep Dive
    • Webinars
    • Podcasts
    • Video
    • White Papers
    • Event
  • Patients
    • News
    • Views & Analysis
    • Deep Dive
    • Webinars
    • Podcasts
    • Video
    • White Papers
    • Event
  • R&D
    • News
    • Views & Analysis
    • Deep Dive
    • Webinars
    • Podcasts
    • Video
    • White Papers
    • Event
  • Sales & Marketing
    • News
    • Views & Analysis
    • Deep Dive
    • Webinars
    • Podcasts
    • Video
    • White Papers
    • Event
  • Spotlight on
    • Frontiers Health 2024
    • Life Science Industry Report
    • World Without Disease Summit

Sign up for email newsletters and Deep Dive

Subscribe
 
 
rss facebook linkedin twitter
Pharmaphorum
About us Advertising Contact us
Contribute Cookie Policy Privacy Policy
Terms & Conditions Work for us
The rights of trademark owners are acknowledged. Website and content copyright © 2009-2025, pharmaphorum media limited or its licensors; all rights reserved. pharmaphorum – an EVERSANA company
The rights of trademark owners are acknowledged. Website and content copyright © 2009-2025, pharmaphorum media limited or its licensors; all rights reserved. pharmaphorum – an EVERSANA company